181 related articles for article (PubMed ID: 16288054)
1. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
2. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
[TBL] [Abstract][Full Text] [Related]
4. HMGA2 and high-grade serous ovarian carcinoma.
Wu J; Wei JJ
J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
[TBL] [Abstract][Full Text] [Related]
5. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
[TBL] [Abstract][Full Text] [Related]
6. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma.
Flavin R; Smyth P; Barrett C; Russell S; Wen H; Wei J; Laios A; O'Toole S; Ring M; Denning K; Li J; Aherne S; Sammarae D; Aziz NA; Alhadi A; Finn SP; Loda M; B S; Sheils O; O'Leary JJ
Int J Gynecol Cancer; 2009 May; 19(4):641-7. PubMed ID: 19509563
[TBL] [Abstract][Full Text] [Related]
7. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.
Gonzalez VD; Samusik N; Chen TJ; Savig ES; Aghaeepour N; Quigley DA; Huang YW; Giangarrà V; Borowsky AD; Hubbard NE; Chen SY; Han G; Ashworth A; Kipps TJ; Berek JS; Nolan GP; Fantl WJ
Cell Rep; 2018 Feb; 22(7):1875-1888. PubMed ID: 29444438
[TBL] [Abstract][Full Text] [Related]
8. Serous surface papillary borderline ovarian tumors: correlation of sonographic features with clinic pathological findings.
Wang D; Su N; Wang R; Zhang L; Qi Z; Liu Z; Yang J; Leng J; Xiang Y;
Ultrasound Obstet Gynecol; 2024 May; 63(5):691-698. PubMed ID: 37592848
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
10. Gene-expression profiling in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Cannistra SA
Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
[TBL] [Abstract][Full Text] [Related]
11. rs66651343 and rs12909095 confer lung cancer risk by regulating CCNDBP1 expression.
Shi Q; Ruan J; Yang YC; Shi XQ; Liu SD; Wang HY; Zhang SJ; Wang SQ; Zhong L; Sun C
PLoS One; 2023; 18(4):e0284347. PubMed ID: 37058478
[TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Farley JH; Brady WE; O'Malley D; Fujiwara K; Yonemori K; Bonebrake A; Secord AA; Stephan JM; Walker JL; Nam JH; Birrer MJ; Gershenson DM
Gynecol Oncol; 2022 Dec; 167(3):423-428. PubMed ID: 36244829
[TBL] [Abstract][Full Text] [Related]
13. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.
Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
[TBL] [Abstract][Full Text] [Related]
14. Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.
Asante DB; Morici M; Mohan GRKA; Acheampong E; Spencer I; Lin W; van Miert P; Gibson S; Beasley AB; Ziman M; Calapre L; Meniawy TM; Gray ES
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944844
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
Li Y; Jaiswal SK; Kaur R; Alsaadi D; Liang X; Drews F; DeLoia JA; Krivak T; Petrykowska HM; Gotea V; Welch L; Elnitski L
BMC Cancer; 2021 Jul; 21(1):768. PubMed ID: 34215221
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer.
Vriend J; Nachtigal MW
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071321
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CXCR2 plays a pivotal role in re-sensitizing ovarian cancer to cisplatin treatment.
Henriques TB; Dos Santos DZ; Dos Santos Guimarães I; Tessarollo NG; Lyra-Junior PCM; Mesquita P; Pádua D; Amaral AL; Cavadas B; Pereira L; Silva IV; Almeida RMDSG; Rangel LBA
Aging (Albany NY); 2021 May; 13(10):13405-13420. PubMed ID: 34038868
[TBL] [Abstract][Full Text] [Related]
18. A prognostic system for epithelial ovarian carcinomas using machine learning.
Grimley PM; Liu Z; Darcy KM; Hueman MT; Wang H; Sheng L; Henson DE; Chen D
Acta Obstet Gynecol Scand; 2021 Aug; 100(8):1511-1519. PubMed ID: 33665831
[TBL] [Abstract][Full Text] [Related]
19. Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers.
Monsivais D; Vasquez YM; Chen F; Zhang Y; Chandrashekar DS; Faver JC; Masand RP; Scheurer ME; Varambally S; Matzuk MM; Creighton CJ
Oncogene; 2021 Mar; 40(11):2081-2095. PubMed ID: 33627787
[TBL] [Abstract][Full Text] [Related]
20. High-grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer.
Jacob F; Marchetti RL; Kind AB; Russell K; Schoetzau A; Heinzelmann-Schwarz VA
Mol Oncol; 2021 Jan; 15(1):91-103. PubMed ID: 33016563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
